WOCKPHARMA - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:04 am

IntraDay Trade Rating: 3.5

📊 Analysis: WOCKPHARMA is trading at 1,411 ₹, slightly above DMA 50 (1,368 ₹) and DMA 200 (1,393 ₹), showing near-term support. RSI at 54.2 indicates neutral momentum, while MACD positive (1.97) suggests mild bullish bias. Volume (5,53,197) is above weekly average (4,71,121), reflecting active participation. However, fundamentals remain weak with high P/E (163), low ROCE (4.40%), and negative ROE (-0.53%). Overall, WOCKPHARMA is a cautious candidate for intraday trading with limited upside potential.

💰 Optimal Buy Price: 1,405–1,415 ₹ (near DMA support zone).

📈 Profit-Taking Levels: 1,430–1,440 ₹ (first resistance), 1,455–1,465 ₹ (second resistance).

⚠️ Stop-Loss: 1,390 ₹ (below DMA 200 support).

⏱️ If Already Holding: Exit intraday if price fails to sustain above 1,420 ₹ or if RSI dips below 52 with MACD flattening. Weakness below 1,405 ₹ should trigger exit to protect capital.

Positive

• ✅ EPS of 8.68 ₹ provides earnings base.
• ✅ PAT growth (+250%) year-on-year highlights operational improvement.
• ✅ Trading above DMA 50 and DMA 200 confirms short-term support.
• ✅ Volume higher than weekly average, showing active participation.

Limitation

• ⚠️ Very high P/E (163) compared to industry average (30.6), indicating overvaluation.
• ⚠️ Low ROCE (4.40%) and negative ROE (-0.53%) show weak efficiency.
• ⚠️ PEG ratio of 6.73 suggests expensive growth.
• ⚠️ Debt-to-equity ratio of 0.76 adds leverage risk.

Company Negative News

• 📉 Decline in FII holding (-0.19%) shows reduced foreign investor confidence.
• 📉 PAT dropped sequentially from 69 Cr. to 54 Cr., raising concerns on earnings consistency.

Company Positive News

• 📈 PAT growth (+250%) year-on-year highlights strong recovery.
• 📈 Stable DII holding and increased trading volume reflect market interest.

Industry

• 🏭 Industry P/E at 30.6 is much lower than company’s P/E, showing sector is relatively cheaper.
• 🏭 Pharma sector remains demand-driven but faces valuation pressure across mid-cap players.

Conclusion

📌 WOCKPHARMA is a cautious candidate for intraday trading with mild bullish bias but weak fundamentals. Buy near 1,405–1,415 ₹ with profit targets at 1,430–1,440 ₹ and 1,455–1,465 ₹. Maintain strict stop-loss at 1,390 ₹. If already holding, exit on failure to sustain above 1,420 ₹ or if RSI/MACD momentum weakens.

Would you like me to extend this into a peer benchmarking overlay so you can compare WOCKPHARMA against other pharma peers for intraday confirmation, or keep the focus on single-stock execution logic?